Abstract: A method and an apparatus for sharing an App, an electronic device and a storage medium are provided. The method includes in response to detecting a preset trigger operation for an App, displaying associated regions for associated devices; in response to a selecting operation for any of the associated regions, determining an associated device corresponding to the any of the associated regions as a target device; and sending interface display data of the App to the target device, so that the target device displays a program interface of the App based on the received interface display data.

Abstract: The present invention relates to the field of medicine, in particular to a composition and use of an SGLT-2 inhibitor and angiotensin receptor blockers, and specifically to a fixed-dose compound composition and use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitor and angiotensin receptor blockers (ARBs). The fixed-dose compound composition is used for the treatment of patients with diabetes and hypertension, and also benefits patients with chronic kidney diseases, preventing or delaying the deterioration of renal failure in patients with chronic kidney diseases (CKD), and preventing cardiovascular (CV) death or death from kidney diseases. In addition, the fixed-dose compound composition has good synergy and good stability, is convenient to carry or administer, significantly reduces the cost of medication, also avoids the risk of excessive and missing administration, and improves the compliance of patients with medication.

Abstract: A sorafenib pharmaceutical composition with high bioavailability and use thereof, and specifically a low-dose sorafenib oral solid preparation, comprising: a) a sorafenib solid dispersion; b) a crystallization inhibitor; and c) additional pharmaceutically acceptable adjuvant. The low-dose sorafenib oral solid preparation has high bioavailability and reduces the dosage of sorafenib such that the same therapeutic effect as that of Nexavar tablets can be achieved when a patient takes orally 35% to 70% of the administered dose of Nexavar tablets; it has higher stability, better safety, and less incidence of side effects; it has lower Cmax and AUC0-t variation, a higher dissolution, and a low crystal precipitation rate with the increase of pH in the gastrointestinal tract; it is easy to be taken by patients due to the small volume of the tablet; it has a fast disintegration speed and a good dissolution effect; and it is easy to realize industrialization.